TOKYO and CAMBRIDGE, Mass., Dec 5, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**…
Read More
